Drugs
Nirsevimab
4 articles published between July 24, 2026 and October 10, 2026.
Covered in Children & Family Health and Science.
WHAT THE STUDY ACTUALLY SAYSA register-based study spanning 181,999 infants and four RSV seasons found acute otitis media dropped 44% and RSV detections 83% in infants under 12 months after a nirsevimab immunisation programme began.
3 min read
WHAT THE STUDY ACTUALLY SAYSA government-funded test-negative study put effectiveness at 86% against emergency visits and 88% against intensive care, though the smallest subgroups carried wide confidence intervals.
4 min read
WHAT THE STUDY ACTUALLY SAYSA test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
4 min read
WHAT THE STUDY ACTUALLY SAYSThe SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.
3 min read
This page indexes this newspaper’s reporting on Nirsevimab. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.